**UNITED      STATES SECURITIES AND EXCHANGE COMMISSION**

**FORM      10-QSB**

** QUARTERLY      REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES      EXCHANGE**

**ACT      OF 1934**

** TRANSITION      REPORT PURSUANT TO SECTION 13 0R 15(D) OF THE SECURITIES      EXCHANGE**

**ACT      OF 1934**

*Commission      File Number: 000-51497*

**BIO-BRIDGE      SCIENCE, INC.**

|   | Delaware                                                |   | 20-1802936                         |   |
|--------|---------------------------------------------------------|--------|------------------------------------|--------|
|   | (State                or Other jurisdiction of          |   | (IRS                Employer       |   |
|   | incorporation                or organization)           |   | Identification                No.) |   |
|   |                                                    |   |                               |   |
|   | 1211                West 22nd Street, Suite 615         |   |                               |   |
|   | Oak                Brook, Illinois                      |   | 60523                              |   |
|   | (Address                of principal executive offices) |   | (Zip                Code)          |   |

----

**Bio-Bridge      Science, Inc**

|                   |                                                                                                                                                                                                                                                                              | Page  |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                1. | Financial                Statements                                                                                                                                                                                                                                               | 3          |
|                   |                                                                                                                                                                                                                                                                              |       |
|                   | Condensed                Consolidated Balance Sheets as of June 30, 2007 (unaudited)                and                December 31, 2006                                                                                                                                          | 3          |
|                   |                                                                                                                                                                                                                                                                              |       |
|                   | Unaudited                  Condensed Consolidated Statements of Operationsfor                the three and six month periods ended June 30, 2007 and 2006                andfor                the period from February 11, 2002 (inception) through June 30,                2007 | 4          |
|                   |                                                                                                                                                                                                                                                                              |       |
|                   | Unaudited                    Condensed Consolidated Statements of Changes in Shareholders'                    Equityand                  Comprehensive Gain (Loss) for the period from February 11, 2002                  (inception)through                June 30, 2007         | 5          |
|                   |                                                                                                                                                                                                                                                                              |       |
|                   | Unaudited                  Condensed Consolidated Statements of Cash Flowsfor                the six month periods ended June 30, 2007 and 2006 andfor                the period from February 11, 2002 (inception) through June 30,                2007                          | 9          |
|                   |                                                                                                                                                                                                                                                                              |       |
|                   | Notes                to Unaudited Condensed Consolidated Financial Statements                                                                                                                                                                                                     | 10         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                2. | Management's                Discussion and Analysis or Plan of Operation                                                                                                                                                                                                          | 19         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                3. | Controls                and Procedures                                                                                                                                                                                                                                            | 24         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Part                II | Other                Information                                                                                                                                                                                                                                                  | 24         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                1. | Legal                Proceedings                                                                                                                                                                                                                                                  | 24         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                2. | Unregistered                Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                        | 25         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                3. | Defaults                Upon Senior Securities                                                                                                                                                                                                                                    | 25         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                4. | Submission                of Matters to a Vote of Security Holders                                                                                                                                                                                                                | 25         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                5. | Other                Information                                                                                                                                                                                                                                                  | 25         |
|                   |                                                                                                                                                                                                                                                                              |       |
| Item                6. | Exhibits                                                                                                                                                                                                                                                                          | 25         |
|                   |                                                                                                                                                                                                                                                                              |       |
|                   | SIGNATURES                                                                                                                                                                                                                                                                        | 25         |

----

**PART      I - FINANCIAL INFORMATION**

**Item      1. Financial Statements**

**BIO-BRIDGE      SCIENCE, INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**CONDENSED      CONSOLIDATED BALANCE SHEETS**

**ASSETS**

|                                                                                                                                                                                                           |   | **June                  30,****2007****(unaudited)** |       | **December                31,****2006** |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------|------------|-----------------------------------------|--------|
| **CURRENT                ASSETS**                                                                                                                                                                              |   |                                                 |       |                                    |   |
| Cash                and cash equivalents                                                                                                                                                                       |   | $                                                    | 426,184    |                                    | $      | 149,613 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| Prepaid                expenses and other current assets                                                                                                                                                       |   |                                                 | 16,194     |                                    |   | 16,828 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| Short                term marketable securities-trading securities                                                                                                                                             |   |                                                 | 1,788,758  |                                    |   | - |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| Note                receivable, net of discount                                                                                                                                                                |   |                                                 | 40,000     |                                    |   | 40,000 |   |
| Total                current assets                                                                                                                                                                            |   |                                                 | 2,271,136  |                                    |   | 206,441 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **FIXED                ASSETS, NET**                                                                                                                                                                           |   |                                                 | 69,159     |                                    |   | 76,238 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **CONSTRUCTION                IN PROGRESS**                                                                                                                                                                    |   |                                                 | 1,720,527  |                                    |   | 1,674,104 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **LAND                USE RIGHT**                                                                                                                                                                              |   |                                                 | 360,207    |                                    |   | 359,658 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **TOTAL                ASSETS**                                                                                                                                                                                |   | $                                                    | 4,421,029  |                                    | $      | 2,316,441 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **LIABILITIES                AND SHAREHOLDERS’                EQUITY**                                                                                                                                   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **CURRENT                LIABILITIES**                                                                                                                                                                         |   |                                                 |       |                                    |   |   |   |
| Accrued                expenses and other payables                                                                                                                                                             |   | $                                                    | 143,434    |                                    | $      | 155,444 |   |
| Amount                due to shareholder                                                                                                                                                                       |   |                                                 | -          |                                    |   | 18,885 |   |
| Payable                to contractors                                                                                                                                                                          |   |                                                 | 118,955    |                                    |   | 474,586 |   |
| Total                current liabilities                                                                                                                                                                       |   |                                                 | 262,389    |                                    |   | 648,915 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **COMMITMENTS                AND                CONTINGENCIES**                                                                                                                                                |   |                                                 |       |                                    |   |   |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **SHAREHOLDERS’                EQUITY**                                                                                                                                                                  |   |                                                 |       |                                    |   |   |   |
| Preferred                stock, $0.001 par value, liquidation preference of $3,000,000, 5,000,000                shares authorized, 4,000,000 and 0 shares issued and outstanding,                respectively |   |                                                 | 4,000      |                                    |   | - |   |
| Common                stock, $0.001 par value, 100,000,000 shares authorized, 34,177,676                and                33,492,001 shares issued and outstanding, respectively                              |   |                                                 | 34,178     |                                    |   | 33,492 |   |
| Additional                paid-in capital                                                                                                                                                                      |   |                                                 | 10,262,383 |                                    |   | 5,469,402 |   |
| Preferred                stock dividend payable in common shares                                                                                                                                               |   |                                                 | 137,000    |                                    |   | - |   |
| Subscription                receivable                                                                                                                                                                         |   |                                                 | (215,020   | )                                       |   | (25,091 | ) |
| Common                stock to be issued, 296,667 and 240,000 shares,                respectively                                                                                                              |   |                                                 | 297        |                                    |   | 240 |   |
| Accumulated                other comprehensive gain                                                                                                                                                            |   |                                                 | 130,340    |                                    |   | 80,403 |   |
| Deficit                accumulated during the development stage                                                                                                                                                |   |                                                 | (6,194,538 | )                                       |   | (3,890,920 | ) |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| Total                shareholders’ equity                                                                                                                                                                |   |                                                 | 4,158,640  |                                    |   | 1,667,526 |   |
|                                                                                                                                                                                                           |   |                                                 |       |                                    |   |   |   |
| **TOTAL                LIABILITIES AND SHAREHOLDERS’ EQUITY**                                                                                                                                            |   | $                                                    | 4,421,029  |                                    | $      | 2,316,441 |   |

----

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

|                                                                                                     |   | **Three                Months Ended June 30, 2007** |       | **Three                Months Ended June 30, 2006** |   | **Six                Months****Ended                June 30, 2007** |   | **Six                Months****Ended                June 30, 2006** |       | **For                the Period from February 11, 2002 (Inception) through June                30, 2007** |   |
|----------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------|------------|-----------------------------------------------------|--------|---------------------------------------------------------------------|--------|---------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------|--------|
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **REVENUE**                                                                                              |   | $                                                   | 333        |                                                | $      | 92                                                                  |   | $                                                                   | 690        |                                                                                                      | $      | 273 |   | $ | 2,458 |   |
| **COST                OF GOODS SOLD**                                                                    |   |                                                | (178       | )                                                   |   | (28                                                                 | )      |                                                                | (405       | )                                                                                                         |   | (84 | ) |   | (1,584 | ) |
| **GROSS                PROFIT**                                                                          |   |                                                | 155        |                                                |   | 64                                                                  |   |                                                                | 285        |                                                                                                      |   | 189 |   |   | 874 |   |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| Research                and development cost                                                             |   |                                                | (38,355    | )                                                   |   | (33,806                                                             | )      |                                                                | (82,050    | )                                                                                                         |   | (50,274 | ) |   | (399,304 | ) |
| Selling                and distribution expenses                                                         |   |                                                | (10,838    | )                                                   |   | (12,800                                                             | )      |                                                                | (16,311    | )                                                                                                         |   | (18,688 | ) |   | (64,464 | ) |
| General                and administrative expenses                                                       |   |                                                | (419,374   | )                                                   |   | (402,206                                                            | )      |                                                                | (718,600   | )                                                                                                         |   | (678,186 | ) |   | (4,256,424 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **LOSS                FROM OPERATIONS**                                                                  |   |                                                | (468,412   | )                                                   |   | (448,748                                                            | )      |                                                                | (816,676   | )                                                                                                         |   | (746,959 | ) |   | (4,719,318 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **UNREALIZED                LOSS ON TRADING SECURITIES**                                                 |   |                                                | (85,360    | )                                                   |   | -                                                                   |   |                                                                | (108,426   | )                                                                                                         |   | - |   |   | (108,426 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **DIVIDEND                AND INTEREST INCOME**                                                          |   |                                                | 38,952     |                                                |   | 882                                                                 |   |                                                                | 51,804     |                                                                                                      |   | 2,007 |   |   | 63,526 |   |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **NET                LOSS**                                                                              |   |                                                | (514,820   | )                                                   |   | (447,866                                                            | )      |                                                                | (873,298   | )                                                                                                         |   | (744,952 | ) |   | (4,764,218 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **DEEMED                PREFERRED STOCK DIVIDEND**                                                       |   |                                                | -          |                                                |   | -                                                                   |   |                                                                | (1,293,320 | )                                                                                                         |   | - |   |   | (1,293,320 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **PREFERRED                STOCK DIVIDENDS**                                                             |   |                                                | (90,000    | )                                                   |   | -                                                                   |   |                                                                | (137,000   | )                                                                                                         |   | - |   |   | (137,000 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **NET                LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS**                                          |   | $                                                   | (604,820   | )                                                   | $      | (447,866                                                            | )      | $                                                                   | (2,303,618 | )                                                                                                         | $      | (744,952 | ) | $ | (6,194,538 | ) |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **LOSS                PER SHARE, attributable to common shareholders, basic and                diluted** |   | $                                                   | (0.02      | )                                                   | $      | (0.01                                                               | )      | $                                                                   | (0.07      | )                                                                                                         | $      | (0.02 | ) |   |   |   |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |
| **WEIGHTED                AVERAGE SHARES OUTSTANDING, basic and diluted**                                |   |                                                | 33,785,874 |                                                |   | 32,906,917                                                          |   |                                                                | 33,720,633 |                                                                                                      |   | 32,712,672 |   |   |   |   |
|                                                                                                     |   |                                                |       |                                                |   |                                                                |   |                                                                |       |                                                                                                      |   |   |   |   |   |   |

----

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH JUNE 30, 2007**

|                                                                   |   |                        |             |    |    | Additional   |   |                 |      |  Common                Stock |    | AccumulatedOther           |    | DeficitAccumulatedDuring                the |    |   |    |
|------------------------------------------------------------------------|--------|-----------------------------|------------------|---------|---------|--------------|--------|----------------------|-----------|-----------------------------------|---------|----------------------------|---------|---------------------------------------------|---------|--------|---------|
|                                                                   |   | Common                Stock |             | Paid-in |    | Deferred     |   | To                be |      | Comprehensive                     |    | Development                |    |                                        |    |
|                                                                   |   | Shares                      |             | Amount  |    | Capital      |   | Compensation         |      | Issued                            |    | Gain                (Loss) |    | Stage                                       |    | Total  |    |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 13,750,000 shares at $0.00004               |   |                        | 13,750,000       |    | $       | 13,750       |   | $                    | (13,200   | )                                 | $       | -                          |    | $                                           | -       |   | $       | - |   | $ | - |   | $ | 550 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 7,461,090 shares at $0.0468                 |   |                        | 7,461,090        |    |    | 7,461        |   |                 | 341,719   |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 349,180 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 1,875,000 shares at $0.12                   |   |                        | 1,875,000        |    |    | 1,875        |   |                 | 223,125   |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 225,000 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Foreign                currency translation loss                       |   |                        | -                |    |    | -            |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | (499 | ) |   | - |   |   | (499 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Net                loss                                                |   |                        | -                |    |    | -            |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | - |   |   | (114,476 | ) |   | (114,476 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| **BALANCE                DECEMBER 31, 2002**                           |   |                        | 23,086,090       |    |    | 23,086       |   |                 | 551,644   |                              |    | -                          |    |                                        | -       |   |    | (499 | ) |   | (114,476 | ) |   | 459,755 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 3,508,425 shares at $0.12                   |   |                        | 3,508,425        |    |    | 3,509        |   |                 | 417,502   |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 421,011 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 201,200 shares at $0.32                     |   |                        | 201,200          |    |    | 201          |   |                 | 64,186    |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 64,387 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Foreign                currency translation loss                       |   |                        | -                |    |    | -            |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | (644 | ) |   | - |   |   | (644 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Net                loss                                                |   |                        | -                |    |    | -            |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | - |   |   | (255,020 | ) |   | (255,020 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| **BALANCE                DECEMBER 31, 2003**                           |   |                        | 26,795,715       |    |    | 26,796       |   |                 | 1,033,332 |                              |    | -                          |    |                                        | -       |   |    | (1,143 | ) |   | (369,496 | ) |   | 689,489 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 434,600 shares at $0.12                     |   |                        | 434,600          |    |    | 435          |   |                 | 51,715    |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 52,150 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 1,125,275 shares at $0.32                   |   |                        | 1,125,275        |    |    | 1,125        |   |                 | 358,961   |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 360,086 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Issuance                of 1,616,000 shares at $0.50                   |   |                        | 1,616,000        |    |    | 1,616        |   |                 | 806,382   |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 807,998 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Fair                market value of Stock options granted for services |   |                        | -                |    |    | -            |   |                 | 695,052   |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 695,052 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Fair                value of shares issued for services                |   |                        | 100,000          |    |    | 100          |   |                 | 49,900    |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 50,000 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Exercise                of options                                     |   |                        | 200,000          |    |    | 200          |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | - |   |   | - |   |   | 200 |   |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Deferred                consulting expenses                            |   |                        | -                |    |    | -            |   |                 | -         |                              |    | (390,890                   | )       |                                        | -       |   |    | - |   |   | - |   |   | (390,890 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Foreign                currency translation loss                       |   |                        | -                |    |    | -            |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | (457 | ) |   | - |   |   | (457 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| Net                loss                                                |   |                        | -                |    |    | -            |   |                 | -         |                              |    | -                          |    |                                        | -       |   |    | - |   |   | (944,437 | ) |   | (944,437 | ) |
|                                                                   |   |                        |                  |    |    |              |   |                 |           |                              |    |                            |    |                                        |         |   |    |  |   |   |  |   |   |  |   |
| **BALANCE                DECEMBER 31, 2004**                      |   |                        |  30,271,590 |         |  $ | 30,272  |   | $                    | 2,995,342 |                              |  $ | (390,890                   | )  |  $                                     | -  |   |  $ | (1,600 | ) |  $ | (1,313,933 | )  |  $ | 1,319,191  |   |

----

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH JUNE 30, 2007**

|                                                             |   |                          |       |    |   | Additional |   |                   |      | Common                  Stock |   | Accumulated Other       |   | Deficit Accumulated During                  the |   |   |   |
|------------------------------------------------------------------|--------|-------------------------------|------------|---------|--------|------------|--------|------------------------|-----------|-------------------------------|--------|------------------------------|--------|-----------------------------------------------------------|--------|--------|--------|
|                                                             |   | Common                  Stock |       | Paid-in |   | Deferred   |   | To                  be |      | Comprehensive                 |   | Development                  |   |                                                      |   |
|                                                             |   | Shares                        |       | Amount  |   | Capital    |   | Compensation           |      | Issued                        |   | Gain                  (Loss) |   | Stage                                                     |   | Total  |   |
| **BALANCE                  DECEMBER 31, 2004**                   |   | $                             | 30,271,590 |    | $      | 30,272     |   | $                      | 2,995,342 |                          | $      | (390,890                     | )      | $                                                         | -      |   | $      | (1,600 | ) | $ | (1,313,933 | ) | $ | 1,319,191 |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                  of 2,179,947 shares at $0.50           |   |                          | 2,179,947  |    |   | 2,180      |   |                   | 1,087,794 |                          |   | -                            |   |                                                      | -      |   |   | - |   |   | - |   |   | 1,089,974 |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Stock                  options issued for services               |   |                          | -          |    |   | -          |   |                   | 34,935    |                          |   | (34,935                      | )      |                                                      | -      |   |   | - |   |   | - |   |   | - |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Stock                  options granted to employees and officers |   |                          | -          |    |   | -          |   |                   | 680,604   |                          |   | (680,604                     | )      |                                                      | -      |   |   | - |   |   | - |   |   | - |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Amortization                  of deferred compensation expenses  |   |                          | -          |    |   | -          |   |                   | -         |                          |   | 458,127                      |   |                                                      | -      |   |   | - |   |   | - |   |   | 458,127 |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Return                  of options                               |   |                          | -          |    |   | -          |   |                   | (139,604  | )                             |   | 139,604                      |   |                                                      | -      |   |   | - |   |   | - |   |   | - |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Exercise                  of options                             |   |                          | -          |    |   | -          |   |                   | (328      | )                             |   | -                            |   |                                                      | 328    |   |   | - |   |   | - |   |   | - |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Foreign                  currency translation loss               |   |                          | -          |    |   | -          |   |                   | -         |                          |   | -                            |   |                                                      | -      |   |   | 26,882 |   |   | - |   |   | 26,882 |   |
|                                                             |   |                          |       |    |   |       |   |                   |      |                          |   |                         |   |                                                      |   |   |   |   |   |   |   |   |   |   |   |
| Net                  loss                                        |   |                          | -          |    |   | -          |   |                   | -         |                          |   | -                            |   |                                                      | -      |   |   | - |   |   | (1,253,093 | ) |   | (1,253,093 | ) |
| **BALANCE                  DECEMBER 31, 2005**                   |   |                          | 32,451,537 |    | $      | 32,452     |   | $                      | 4,658,743 |                          | $      | (508,698                     | )      | $                                                         | 328    |   | $      | 25,282 |   | $ | (2,567,026 | ) | $ | 1,641,081 |   |

----

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH JUNE 30, 2007**

|                                                                                                          |   |                                    |       |                |   |  Additional  |   |                             |      |  Common                Stock  |   |  AccumulatedOther            |   |                    |   |  DeficitAccumulatedDuring                the  |   |              |   |
|---------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------|------------|---------------------|--------|------------------------|--------|----------------------------------|-----------|-----------------------------------------|--------|----------------------------------------|--------|-------------------------|--------|---------------------------------------------------------|--------|-------------------|--------|
|                                                                                                          |   |  Common                Stock  |       |  Paid-in  |   |  Deferred    |   |  To                be  |      |  Comprehensive                |   |  Subscriptions               |   |  Development  |   |                                                    |   |
|                                                                                                          |   |  Shares                       |       |  Amount   |   |  Capital     |   |  Compensation          |      |  Issued                       |   |  Gain                (Loss)  |   |  Receivable   |   |  Stage                                        |   |  Total  |   |
| **BALANCE                DECEMBER 31, 2005**                                                                  |   |                                    | 32,451,537 |                | $      | 32,452                 |   | $                                | 4,658,743 |                                    | $      | (508,698                               | )      | $                       | 328    |                                                    | $      | 25,282            |   | $ | - |   | $ | (2,567,026 | ) | $ | 1,641,081 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Reclassification                of deferred compensation balance to                additional-paid-in-capital |   |                                    | -          |                |   | -                      |   |                             | (508,698  | )                                       |   | 508,698                                |   |                    | -      |                                                    |   | -                 |   |   | - |   |   | - |   |   | - |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Issuance                of shares for previously exercised stock option                                       |   |                                    | 328,116    |                |   | 328                    |   |                             | -         |                                    |   | -                                      |   |                    | (328   | )                                                       |   | -                 |   |   | - |   |   | - |   |   | - |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Sales                of shares at $0.75 to $1.2 per share for cash, net of issuance                costs      |   |                                    | 540,348    |                |   | 540                    |   |                             | 872,637   |                                    |   | -                                      |   |                    | 240    |                                                    |   | -                 |   |   | (25,091 | ) |   | - |   |   | 848,326 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Compensatory                shares issued to consultant                                                       |   |                                    | 122,000    |                |   | 122                    |   |                             | 223,773   |                                    |   | -                                      |   |                    | -      |                                                    |   | -                 |   |   | - |   |   | - |   |   | 223,895 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Employee                stock options                                                                         |   |                                    | -          |                |   | -                      |   |                             | 174,670   |                                    |   | -                                      |   |                    | -      |                                                    |   | -                 |   |   | - |   |   | - |   |   | 174,670 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Consultant                stock options                                                                       |   |                                    | -          |                |   | -                      |   |                             | 48,277    |                                    |   | -                                      |   |                    | -      |                                                    |   | -                 |   |   | - |   |   | - |   |   | 48,277 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Exercise                of options                                                                            |   |                                    | 50,000     |                |   | 50                     |   |                             | -         |                                    |   | -                                      |   |                    | -      |                                                    |   | -                 |   |   | - |   |   | - |   |   | 50 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Foreign                currency translation loss                                                              |   |                                    | -          |                |   | -                      |   |                             | -         |                                    |   | -                                      |   |                    |   |                                                    |   | 55,121            |   |   | - |   |   | - |   |   | 55,121 |   |
|                                                                                                          |   |                                    |       |                |   |                   |   |                             |      |                                    |   |                                   |   |                    |   |                                                    |   |              |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                                                                       |   |                                    | -          |                |   | -                      |   |                             | -         |                                    |   | -                                      |   |                    | -      |                                                    |   | -                 |   |   | - |   |   | (1,323,894 | ) |   | (1,323,894 | ) |
| **BALANCE                DECEMBER 31, 2006**                                                                  |   |                                    | 33,492,001 |                | $      | 33,492                 |   | $                                | 5,469,402 |                                    | $      | -                                      |   | $                       | 240    |                                                    | $      | 80,403            |   | $ | (25,091 | ) | $ | (3,890,920 | ) | $ | 1,667,526 |   |

----

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH JUNE 30, 2007**

|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      | Preferred            |    |          |   |          |    |                       |   |       |   |                          |   |   |   |
|--------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------|------------|--------------------------------|--------|----------------|--------|---------|-----------|----------------------|---------|---------------|--------|---------------|---------|----------------------------|--------|------------|--------|-------------------------------|--------|--------|--------|
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      | Stock                |    |          |   |          |    |                       |   |       |   |                  Deficit |   |   |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      | Dividend             |    |          |   | Common        |    | Accumulated                |   |       |   | Accumulated                   |   |   |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      | Payable              |    | Additional    |   | Stock         |    | Other                      |   |       |   | During                the     |   |   |   |
|                                                                                                                                 |   | Common                Stock |       | Preferred                Stock |   | in Common |   | Paid-in |      | To                be |    | Comprehensive |   | Subscriptions |    | Development                |   |       |   |
|                                                                                                                                 |   | Shares                      |       | Amount                         |   | Shares         |   | Amount  |      | Shares               |    | Capital       |   | Issued        |    | Gain                (Loss) |   | Receivable |   | Stage                         |   | Total  |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |
| **BALANCE                DECEMBER 31, 2006**                                                                                         |   |                        | 33,492,001 |                           | $      | 33,492         |   |    | -         |                 | $       | -             |   | $             | -       |                       | $      | 5,469,402  |   | $                             | 240    |   | $      | 80,403 |   | $ | (25,091 | ) | $ | (3,890,920 | ) | $ | 1,667,526 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                of preferred shares at $0.75 per share for cash, net of Issuance                costs                        |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   | 222,203    |   |                          | 297    |   |   |   |   |   | (200,000) |   |   |   |   |   | 22,500 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                of preferred shares at $0.75 per share for cash, net of issuance                costs                        |   |                        | -          |                           |   | -              |   |    | 4,000,000 |                 |    | 4,000         |   |          | -       |                       |   | 2,996,000  |   |                          | -      |   |   | - |   |   | - |   |   | - |   |   | 3,000,000 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Deemed                dividend related to beneficial conversion feature of convertible                preferred                stock |   |                        | -          |                           |   | -              |   |    | -         |                 |    | -             |   |          | -       |                       |   | 1,293,320  |   |                          | -      |   |   | - |   |   | - |   |   | (1,293,320 | ) |   | - |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Accrual                of preferred stock dividend                                                                                   |   |                        | -          |                           |   | -              |   |    | -         |                 |    | -             |   |          | 137,000 |                       |   | -          |   |                          | -      |   |   | - |   |   | - |   |   | (137,000 | ) |   | - |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Compensatory                shares issued                                                                                            |   |                        | 30,000     |                           |   | 30             |   |    | -         |                 |    | -             |   |          | -       |                       |   | 47,714     |   |                          | **-**  |   |   | - |   |   | - |   |   | - |   |   | 47,744 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Fair                value of vested stock options                                                                                    |   |                        | -          |                           |   | -              |   |    | -         |                 |    | -             |   |          | -       |                       |   | 233,744    |   |                          | -      |   |   | - |   |   | - |   |   | - |   |   | 233,744 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                of shares for previously exercised stock option                                                              |   |                        | 240,000    |                           |   | 240            |   |    | -         |                 |    | -             |   |          | -       |                       |   | -          |   |                          | (240   | )      |   | - |   |   | - |   |   | - |   |   | - |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Proceeds                fromPreviously                issued stock                                                                   |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   | 10,071 |   |   |   |   |   | 10,071 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Exercise                of options                                                                                                   |   |                        | 415,675    |                           |   | 416            |   |    | -         |                 |    | -             |   |          | -       |                       |   | -          |   |                          | -      |   |   |   |   |   | - |   |   | - |   |   | 416 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign                currency translation loss                                                                                     |   |                        | -          |                           |   | -              |   |    | -         |                 |    | -             |   |          | -       |                       |   | -          |   |                          | -      |   |   | 49,937 |   |   | - |   |   | - |   |   | 49,937 |   |
|                                                                                                                                 |   |                        |       |                           |   |           |   |    |      |                 |    |          |   |          |    |                       |   |       |   |                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net                loss 1/1/07 to 6/30/07                                                                                            |   |                        | -          |                           |   | -              |   |    | -         |                 |    | -             |   |          | -       |                       |   | -          |   |                          | -      |   |   | - |   |   | - |   |   | (873,298 | ) |   | (873,298 | ) |
| **BALANCE                June 30, 2007****(unaudited)**                                                                              |   |                        | 34,177,676 |                           | $      | 34,178         |   |    | 4,000,000 |                 |  $ | 4,000         |   | $             | 137,000 |                       | $      | 10,262,383 |   | $                             | 297    |   | $      | 130,340 |   | $ | (215,020 | ) | $ | (6,194,538 | ) | $ | 4,158,640 |   |

----

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

|                                                                                                      |   | **For                six months****Ended June 30,                2007** |       | **For                six months Ended June 30, 2006** |   | **For                the Period From February 11, 2002 (Inception) Through June                30, 2007** |   |
|-----------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------|------------|-----------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------|--------|
| **CASH                FLOWS FROM OPERATING ACTIVITIES**                                                   |   |                                                                              |       |                                                            |   |                                                                                                      |   |
| Net                loss                                                                                   |   | $                                                                                 | (873,298   | )                                                               | $      | (744,952                                                                                                  | )      | $ | (4,764,218 | ) |
| Adjustments                to reconcile net loss to net cash used in operating                activities: |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| Depreciation                                                                                              |   |                                                                              | 9,408      |                                                            |   | 3,371                                                                                                     |   |   | 34,295 |   |
| Amortization                of land use right                                                             |   |                                                                              | 8,469      |                                                            |   | 8,130                                                                                                     |   |   | 64,568 |   |
| Non                cash stock compensation expense                                                        |   |                                                                              | 281,487    |                                                            |   | 245,610                                                                                                   |   |   | 1,490,618 |   |
| Unrealized                loss on trading securities                                                      |   |                                                                              | 108,426    |                                                            |   | -                                                                                                         |   |   | 108,426 |   |
| Stock                issued for services                                                                  |   |                                                                              | -          |                                                            |   | -                                                                                                         |   |   | 50,000 |   |
| Loss                on sale of investment                                                                 |   |                                                                              | -          |                                                            |   | -                                                                                                         |   |   | 2,107 |   |
| Decrease                (increase) in prepaid expense and other assets                                    |   |                                                                              | 633        |                                                            |   | (6,700                                                                                                    | )      |   | (46,548 | ) |
| Decrease                (increase) in payable to contractor                                               |   |                                                                              | (355,631   | )                                                               |   | -                                                                                                         |   |   | 118,955 |   |
| Increase                in accrued expenses and other payable                                             |   |                                                                              | (12,010    | )                                                               |   | 68,724                                                                                                    |   |   | 143,434 |   |
| Net                Cash Used In Operating Activities                                                      |   |                                                                              | (832,516   | )                                                               |   | (425,817                                                                                                  | )      |   | (2,798,363 | ) |
|                                                                                                      |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| **CASH                FLOWS FROM INVESTING ACTIVITIES**                                                   |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| Purchase                of land use right                                                                 |   |                                                                              | -          |                                                            |   | -                                                                                                         |   |   | (394,559 | ) |
| Increase                in construction in progress                                                       |   |                                                                              | (3,951     | )                                                               |   | (247,295                                                                                                  | )      |   | (1,668,789 | ) |
| Purchase                of fixed assets                                                                   |   |                                                                              | (720       | )                                                               |   | (42,382                                                                                                   | )      |   | (102,360 | ) |
| Purchase                of investment                                                                     |   |                                                                              | -          |                                                            |   | -                                                                                                         |   |   | (40,000 | ) |
| Purchase                of marketable securities                                                          |   |                                                                              | (2,000,000 | )                                                               |   | -                                                                                                         |   |   | (2,000,000 | ) |
| Proceeds                from sale of of marketable securities                                             |   |                                                                              | 102,816    |                                                            |   | -                                                                                                         |   |   | 102,816 |   |
| Advance                to employees                                                                       |   |                                                                              | -          |                                                            |   | (5,983)                                                                                                   |   |   | 19,070 |   |
| Net                Cash Used In Investing Activities                                                      |   |                                                                              | (1,901,855 | )                                                               |   | (295,660                                                                                                  | )      |   | (4,083,822 | ) |
|                                                                                                      |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| **CASH                FLOWS FROM FINANCING ACTIVITIES**                                                   |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| Proceeds                from issuance of common stock                                                     |   |                                                                              | 22,500     |                                                            |   | 618,396                                                                                                   |   |   | 4,241,412 |   |
| Proceeds                from issuance of preferred stock                                                  |   |                                                                              | 3,000,000  |                                                            |   | -                                                                                                         |   |   | 3,000,000 |   |
| Proceeds                from issuance of previously issued stock                                          |   |                                                                              | 10,071     |                                                            |   | -                                                                                                         |   |   | 10,071 |   |
| Proceeds                from exercise of stock option                                                     |   |                                                                              | 416        |                                                            |   | -                                                                                                         |   |   | 416 |   |
| Amount                due to shareholders                                                                 |   |                                                                              | (18,885)   |                                                            |   | -                                                                                                         |   |   | - |   |
| Net                Cash Provided By Financing Activities                                                  |   |                                                                              | 3,014,102  |                                                            |   | 618,396                                                                                                   |   |   | 7,251,899 |   |
|                                                                                                      |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| **NET                INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS**                                   |   |                                                                              | 279,731    |                                                            |   | (103,081                                                                                                  | )      |   | 369,714 |   |
|                                                                                                      |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| Effect                of exchange rate changes on cash                                                    |   |                                                                              | (3,160)    |                                                            |   | 11,686                                                                                                    |   |   | 56,470 |   |
| Cash                and cash equivalents, beginning of period                                             |   |                                                                              | 149,613    |                                                            |   | 385,646                                                                                                   |   |   | - |   |
|                                                                                                      |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| **CASH                AND CASH EQUIVALENTS, END OF PERIOD**                                               |   | $                                                                                 | 426,184    |                                                            | $      | 294,251                                                                                                   |   | $ | 426,184 |   |
|                                                                                                      |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| **SUPPLEMENTAL                CASH FLOW INFORMATION**                                                     |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| Interest                Paid                                                                              |   | $                                                                                 | -          |                                                            | $      | -                                                                                                         |   | $ | - |   |
| Income                taxes Paid                                                                          |   | $                                                                                 | -          |                                                            | $      | -                                                                                                         |   | $ | - |   |
| **SUPPLEMENTAL                NON-CASH INVESTING AND FINANCING ACTIVITIES**                               |   |                                                                              |       |                                                            |   |                                                                                                      |   |   |   |   |
| Deemed                preferred stock dividend                                                            | $      |                                                                              | 1,293,320  |                                                            | $      | -                                                                                                         |   | $ | 1,293,320 |   |
| Preferred                stock dividend                                                                   | $      |                                                                              | 137,000    |                                                            | $      | -                                                                                                         |   | $ | 137,000 |   |

----

**BIO-BRIDGE      SCIENCE, INC. AND SUBSIDIARIES**

**NOTES      TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL**

**STATEMENTS      AS OF JUNE 30, 2007**

**NOTE      1 - BASIS OF PRESENTATION**

**NOTE      2 - ORGANIZATION AND PRINCIPAL ACTIVITIES**

History      of losses and negative cash flows

----

**NOTE      3-SUMMARY OF PRINCIPAL ACCOUNTING POLICIES**

The      Company’s trading      securities are carried at fair value with changes in fair value recognized      in      current period consolidated statements of operations. Gains or losses realized      upon sale of all securities are recognized in other income or expense at the      time of sale.

|                                                      |   | 2007   |   | 2006   |   |
|-----------------------------------------------------------|--------|--------|--------|--------|--------|
| Quarter                / Year end RMB : US$ exchange rate |   |   | 7.6155 |   |   | 7.8087 |   |
| Average                yearly RMB : US$ exchange rate     |   |   | 7.6749 |   |   | 7.9395 |   |

----

On      January 1, 2006, the Company adopted SFAS No. 123 (revised 2004), “Share-Based      Payment,” (SFAS 123R) which requires the measurement and recognition of      compensation expense for all stock-based awards based upon the grant-date fair      value of those awards. We previously accounted for our stock-based awards under      SFAS No. 123, "Accounting for Stock-Based Compensation" which was similar to      SFAS 123R whereby the fair value of option and warrant grants was determined      using the Black-Scholes option pricing model at the date of grant We adopted      SFAS No. 123R, and its related implementation guidance as promulgated by both      the Financial Accounting Standards Board ( the "FASB"), and the Securities      and      Exchange Commission ("SEC") Staff Accounting Bulletin ("SAB") No 107 (“SAB      107”), associated with the accounting for stock-based compensation arrangements      of our employees and directors. These pronouncements require that equity-based      compensation cost be measured at the grant date (based upon an estimate of      the      fair value of the compensation granted) and recorded to expense over the      requisite service period, which generally is the vesting period.

----

EITF      No.      96-18, “Accounting for Equity Instruments that are Issued to Other than      Employees for Acquiring, or in Conjunction with Selling, Goods or Services”(EITF 96-18) for our non-employee stock-based awards. Under EITF 96-18, the      measurement date at which the fair value of the stock-based award is measured      is      equal to the earlier of 1) the date at which a commitment for performance by      the      counterparty to earn the equity instrument is reached or 2) the date at which      the counterparty’s performance is complete. We recognize stock-based      compensation expense for the fair value of the vested portion of non-employee      awards in our consolidated statements of operations.

*Accounting      for Registration Payment Arrangements*
*Accounting      for Contingencies*

* *
* *

* *
* *

**NOTE 4      - SHAREHOLDER'S EQUITY**

----

**ISSUANCE      OF 4,000,000 PERFERRED SHARES AT $ 0.75 PER SHARE FOR TOTAL CONSIDERATION OF      $3,000,000**

certain      anti-dilution protection.

----

**ISSUANCE      OF COMMON STOCK FOR SERVICES**

On      March      6, 2006, we engaged CH Capital LLC for financial consulting services and agreed      to issue a total of 50,000 shares of common stock for these financial consulting      services. 25,000 shares were issued on March 6, 2006 and an additional 25,000      shares were issued on September 6, 2006. The fair value of the 50,000 shares      was      $101,250 and was determined as follows: the value of the first 25,000 shares      was      calculated using the closing share price of $1.80 on March 6, 2006 and the      value      of the remaining 25,000 shares was calculated using the closing share price      of      $2.25 on September 6, 2006. The Company had amortized $83,506 as compensation      cost in 2006. The Company has amortized the total of $101,250 as compensation      cost as of March 31 2007.

**EXERCISE      OF STOCK OPTIONS**

----

On      October 14, 2005, the Company issued to Mr. Liang Qiao, MD, the Company's chief      executive officer, an option to purchase 600,000 shares of common stock at      $0.55      per share to be exercised with a ten-year (10) period. The options granted      were      valued at $157,770 at the date of grant, which was determined by the      Black-Scholes valuation method, using the following assumptions: no expected      dividend yield; risk-free interest rates of 3.4%; expected lives of four years;      and estimated volatility of 70 percent based on recent history of the stock      price in the industry. The value of the options will be amortized over the      three      year vesting period. For quarter ended June 30, 2007, $13,150 has been amortized      and included in the accompanying statement of operations.

----

**INVESTMENT      AGREEMENT**

On      November 29, 2005, the Company and Dutchess entered into a Registration Rights      Agreement. Pursuant to the Registration Rights Agreement, the Company is      required to file a registration statement within 30 days for purposes of      registering the resale of 2,000,000 shares of common stock to be issued under      the terms of the Agreement. Other than in respect of this transaction, there      are      no material relationships between the Company and Dutchess, or their respective      affiliates.

**NOTE      5-STOCK OPTION PLAN**

|                                          |   | Options                Granted |      | Weighted                AverageExercise                Price |   |
|-----------------------------------------------|--------|--------------------------------|-----------|--------------------------------------------------------------|--------|
|                                          |   |                           |      |                                                         |   |   |   |
| Outstanding                at January 1, 2007 |   |                           | 2,685,675 |                                                         | $      | 0.37 |   |
|                                          |   |                           |      |                                                         |   |   |   |
| Granted                                       |   |                           | 120,000   |                                                         |   | 0.001 |   |
| Exercised                                     |   |                           | (415,675  | )                                                            | $      | 0.001 |   |
| Withdrawn                                     |   |                           | (5,000    | )                                                            | $      | 0.001 |   |
|                                          |   |                           |      |                                                         |   |   |   |
| Outstanding                at June 30, 2007   |   |                           | 2,385,000 |                                                         | $      | 0.41 |   |
|                                          |   |                           |      |                                                         |   |   |   |
| Exercisable                at June 30, 2007   |   |                           | 1,587,084 |                                                         | $      | 0.36 |   |

----

|                                    |   | Options                Outstanding |      | Options                Exercisable                            |   |
|-----------------------------------------|--------|------------------------------------|-----------|---------------------------------------------------------------|--------|
| Range                of Exercise Prices |   | Number                of Shares    |      | Weighted                Average Exercise                Price |   | Weighted                AverageRemaining                Contractual Life (in years) |   | Number                of Shares |   | Weighted                Average Exercise Price |   |
|                                    |   |                               |      |                                                          |   |   |   |   |   |   |   |
| $0.001                to $0.55          |   |                               | 2,385,000 |                                                          |   | $0.41 |   |   | 1 |   |   | 1,587,084 |   |   | $0.36 |   |
|                                    |   |                               | 2,385,000 |                                                          |   |   |   |   |   |   |   | 1,587,084 |   |   |   |   |

|                                        |   | Shares |      |
|---------------------------------------------|--------|--------|-----------|
|                                        |   |   |      |   |
| Nonvested                at January 1, 2007 |   |   | 1,120,000 |   |
| Granted                                     |   |   | -         |   |
| Vested                                      |   |   | (319,584  | ) |
| Withdrawn                                   |   |   | (2,500    | ) |
| Nonvested                at June 30, 2007   |   |   | 797,916   |   |

**NOTE 6      - COMMITMENTS AND CONTINGENCIES**

----

**Item      2. Management's Discussion and Analysis or Plan of      Operation**

----

**OVERVIEW**

**Plan      of Operation**

We      plan      to develop three more products in the near future to diversify our potential      product offerings, and these new potential products are summarized as      follows:

| o | HPV                preventive and therapeutic vaccines - an oral vaccine that will be                used to                prevent and treat HPV6, 11, 16, 18, 31, 45, and 58 infection (cover                >90% of HPV causing cervical                cancer). |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| o | Colon                cancer therapeutic vaccine--an oral vaccine that treats CEA+ colon                cancer. |
|---|----------------------------------------------------------------------------------------------------------------|

| o | Mucosal                adjuvant -- an adjuvant that can be used to enhance vaccines efficacy                in                elderly, e.g. for influenza virus vaccine for age over                60. |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| o | approximately                $0.7 million for our laboratory/bio-manufacturing facility’s steam and                electricity work for Phase I laboratory manufacturing facility project                in                Beijing, China; |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| o | approximately                $1.0 million to purchase advanced laboratory equipment and supplies                for                our vaccine production; |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| o | approximately                $0.5 million to finish Phase I clinical study and the preparatory                work; |
|---|---------------------------------------------------------------------------------------------------------------------|

| o | approximately                $1.0 million for working capital and general corporate needs;                and |
|---|---------------------------------------------------------------------------------------------------------------|

| o | approximately                $0.6 million for pre-clinical trials on HPV vaccines, colon cancer                vaccine, and mucosal adjuvant. |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------|

We      signed      an exclusive agency agreement with Xinhua Surgical Instruments Co. Ltd. to      distribute its operational instruments in the United States at the end of 2005.      We are currently forming a sales team and seeking collaboration with local      distributors and developing markets for Xinhua instruments. As these activities      will take significant amount of time, we do not expect to generate any      significant revenues in the next 12 months.

**Results      of Operations**

**Three-month      period ended June 30, 2007 and June 30, 2006**

----

**Liquidity      and Capital Resources**

**Critical      Accounting Policies**

----

*Accounting      for Registration Payment Arrangements*
*Accounting      for Contingencies*

**Recent      Accounting Pronouncements**

* *

* *
* *

----

* *

**Lease      Commitment**

**Royalty      and License Arrangements**

**Contractual      Obligations**

|                                   |   |                  Payments due by period ($ in thousands) |   |
|----------------------------------------|--------|---------------------------------------------------------------|--------|
| Contractual                Obligations |   | Total                                                         |   | Less                than 1 year |   | 1                to 3 years |   |
|                                   |   |                                                          |   |   |   |   |   |
| Lease                obligation        |   |                                                          | 105    |   |   | 21 |   |   | 84 |   |
|                                   |   |                                                          |   |   |   |   |   |   |   |   |
| Total                                  |   | $                                                             | 105    |   | $ | 21 |   |   | 84 |   |

**Item      3. Controls and Procedures**

**PART      II - OTHER INFORMATION**

**Item      1. Legal Proceedings**

----

**Item      2. Unregistered Sales of Equity Securities and Use of      Proceeds**

**Item      3. Defaults Upon Senior Securities**

**Item      4. Submission of Matters to a Vote of Security Holders**

**Item      5. Other Information**

**Item      6. Exhibits**

**SIGNATURES**

**Bio-Bridge      Science, Inc.**

|   |                                                  |   |                                    |   |
|--------|-------------------------------------------------------|--------|-----------------------------------------|--------|
|   | */s/                Dr. Liang Qiao*                   |   |                                    |   |
|   | *By:                Dr. Liang Qiao*                   |   | *Dated:                August 10, 2007* |   |
|   | *                  Chief Executive Officer* |   |                                    |   |

----

**EXHIBIT      INDEX**

| 3.1(i)*    | Certificate                of incorporation of the registrant, as currently in                effect             |
|------------|------------------------------------------------------------------------------------------------------------------|
|       |                                                                                                             |
| 3.1(ii)*   | Bylaws                of the registrant, as currently in effect                                                  |
|       |                                                                                                             |
| 3.1(iii)** | Certificate                of Designation of Series A Preferred Stock                                            |
|       |                                                                                                             |
| 4.1**      | Form                of Common Stock Warrant Agreement dated January 2007                                         |
|       |                                                                                                             |
| 4.2**      | Registration                Rights Agreement dated January 2007                                                  |
|       |                                                                                                             |
| 4.3        | First                Amendment to Lease                                                                          |
|       |                                                                                                             |
| 4.4        | Lease                agreement between Bio Bridge Science (Beijing) Corporation and Wenhui                Qiao   |
|       |                                                                                                             |
| 4.5        | Lease                agreement between Bio Bridge Science (Beijing) Corporation and Minjin                Yu     |
|       |                                                                                                             |
| 10.1**     | Securities                Purchase Agreement dated January 2007                                                  |
|       |                                                                                                             |
| 31.1       | Certification                of Chief Executive Officer                                                          |
|       |                                                                                                             |
| 31.2       | Certification                of Chief Financial Officer                                                          |
|       |                                                                                                             |
| 32.1       | Section                1350 Certifications of Chief Executive Officer and Chief Financial                Officer |

----